Our family planning work in Senegal
PATH partners with the public and private sectors to improve the health of women and children and increase access to reproductive health services. For example, we worked with the Senegalese Ministry of Health to identify groups who may benefit from public-sector distribution of family planning services. We also work with nongovernmental organizations and civil-society partners to ensure modern contraceptive options are available to women throughout Senegal.
Sécurité Contraceptive en Afrique Francophone (SECONAF)
The Reproductive Health Supplies Coalition is a global partnership of more than 200 public, private, and nongovernmental organizations with the vision of ensuring that all people in low- and middle-income countries can access and use affordable, high-quality supplies and related services to ensure their better reproductive health. The Brussels-headquartered Secretariat is staffed and managed by PATH.
The coalition and regional partners established a forum focused on reproductive health commodity security in Francophone Africa, known as Sécurité Contraceptive en Afrique Francophone (SECONAF) in June 2011. The forum has rapidly grown from 18 members from 6 countries at inception to more than 170 members from 29 countries in January 2013.
The ultimate goal of the forum matches the coalition’s vision, and the purpose of the forum is to facilitate and promote the successful application of the latest knowledge and to develop the understanding and capacity needed to accelerate reproductive health commodity security in Francophone Africa.
- Read more about Forum Francophone SECONAF from the Reproductive Health Supplies Coalition website
Introduction and evaluation of Sayana® Press
Injectable contraceptives are among the world’s most popular methods for preventing pregnancy, offering women safe and effective protection, convenience, and privacy.
Sayana® Press is a new, three-month, progestin-only injectable contraceptive packaged in the Uniject™ injection system, a small, prefilled, autodisable device. It contains 104 mg of depot medroxyprogesterone acetate (DMPA) and is administered via subcutaneous injection. Sayana Press has the potential to improve injectable contraceptive access by increasing the ease, safety, and reach of non-clinic delivery through means such as community-based distribution and social marketing. While Sayana Press is not currently labeled for self-injection, in the future it may offer women more control over their use of contraception through home or self-injection.
Beginning in January 2013, the project aims to make Sayana Press available through normal delivery channels in five countries, including Senegal, and build the evidence base for decision-making about whether and how countries can include Sayana Press in family planning programs in the future. An initial 12 million units of Sayana Press are being procured by donors involved in the 2012 London Summit on Family Planning to reach new users through pilot introduction in the five countries. The Bill & Melinda Gates Foundation funds PATH to oversee product procurement, facilitate the introduction process, and evaluate introduction efforts in participating countries.
Sayana Press is expected to increase contraceptive access and reach new users rather than replace the intramuscular presentation of DMPA, which is being used successfully in a number of delivery settings. In Senegal, the project will evaluate the product’s impact on expanding access to injectables for new users, improving contraceptive continuation rates, and reducing service-delivery costs. The evidence generated will enable governments, nongovernmental organizations, donors, and procurers to make informed purchasing and programming decisions regarding inclusion of Sayana Press in the family planning method mix.
- Read more about Sayana Press on PATH website
Sayana Press is a registered trademark of Pfizer, Inc.
Uniject is a trademark of BD.